Objective tumor response by iRECIST
| dMMR (n=36) | pMMR (n=35) | |||
| Best OTRR | 17 | 47% (95% CI 32% to 63%) | 1 | 3% (95% CI 1% to 15%) |
| OTRR by lines of prior chemotherapy, n (%) | ||||
| 0 | 12 (57) | 0 (0) | ||
| 1 | 5 (38) | 1 (5) | ||
| 2/ > | 0 (0) | 0 (0) | ||
| Best overall response, n (%) | ||||
| iCR | 6 (17) | 0 (0) | ||
| iPR | 11 (31) | 1 (3) | ||
| iSD | 6 (17) | 10 (29) | ||
| iCPD | 13 (36) | 23 (66) | ||
| DCR at 16 weeks | 21 (58) | 8 (23) | ||
| DCR at 24 weeks | 18 (50) | 7 (20) | ||
DCR, disease control rate; dMMR, mismatch repair deficient; iCPD, confirmed progressive disease by iRECIST; iCR, complete response by iRECIST; iPR, partial response by iRECIST; iRECIST, RECIST V.1.1 modified for immune-based therapeutics; iSD, stable disease by iRECIST; OTRR, objective tumor response rate; pMMR, mismatch repair proficient.